GLSI Share Price Performance
US$10.31
-2.59 (-20.08%)
97.8% undervalued intrinsic discount
US$460.00
Fair Value
Price US$10.31
White_valkyrie US$460.00
Fair ValueUS$460.00
Share Pricen/a
Greenwich LifeSciences, Inc. Stock Price
- 1 Narratives written by author
- 1 Comments on narratives written by author
- 26 Fair Values set on narratives written by author
GLSI Community Narratives
WH
Fair Value US$460 97.8% undervalued intrinsic discount
Greenwich LifeSciences will eye a valued future at $460 a share, with GP2 leading the way.
5users have liked this narrative
1users have commented on this narrative
17users have followed this narrative
Greenwich LifeSciences will eye a valued future at $460 a share, with GP2 leading the way.
*DISCLAIMER: *This article is NOT financial advice of any kind, i am NOT a financial adviser, this content should NOT be construed as an offer, recommendation or inducement to buy or sell Greenwich Lifesciences $GLSI stock. Do yor own Due diligence with this type of products before taking from granted any of these opinions.Read more
731
users have viewed this narrative5users have liked this narrative
1users have commented on this narrative
17users have followed this narrative
WH
US$460
97.8% undervalued intrinsic discount
White_valkyrie's Fair Value
Profit Margin
49%
Future PE
26x
Price in 2029
US$0
Trending Discussion
Recently Updated Narratives
WH
Greenwich LifeSciences will eye a valued future at $460 a share, with GP2 leading the way.
Fair Value: US$460 97.8% undervalued intrinsic discount
17 followersusers have followed this narrative
1 commentusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Greenwich LifeSciences, Inc. Key Details
About GLSI
- Founded
- 2006
- Employees
- 6
- CEO
- WebsiteView website
Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers in the United States and Romania. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company also develops FLAMINGO-01, which is in Phase III clinical trial designed to evaluate the safety and efficacy of GLSI-100 (GP2 + GM-CSF) in HER2 positive breast cancer patients. Greenwich LifeSciences, Inc. was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. The company was incorporated in 2006 and is headquartered in Stafford, Texas.
